Pregled bibliografske jedinice broj: 728786
New European guidelines for pulmonary embolism: the role of novel oral direct anticoagulants
New European guidelines for pulmonary embolism: the role of novel oral direct anticoagulants // Cardiologia Croatica. 2014 ; 9(9-10):325-520. / Ivanuša, Mario ; Čikeš, Maja ; Miličić, Davor (ur.).
Zagreb: Hrvatsko kardiološko društvo, 2014. str. 333-333 (predavanje, domaća recenzija, sažetak, znanstveni)
CROSBI ID: 728786 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
New European guidelines for pulmonary embolism: the role of novel oral direct anticoagulants
Autori
Zaputović, Luka
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Cardiologia Croatica. 2014 ; 9(9-10):325-520.
/ Ivanuša, Mario ; Čikeš, Maja ; Miličić, Davor - Zagreb : Hrvatsko kardiološko društvo, 2014, 333-333
Skup
10. kongres Hrvatskoga kardiološkog društva
Mjesto i datum
Zagreb, Hrvatska, 06.11.2014. - 09.11.2014
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Domaća recenzija
Ključne riječi
venous thromboembolism; pulmonary embolism; anticoagulants
Sažetak
The term venous thromboembolism (VTE) includes deep vein thrombosis (DVT) and pulmonary embolism (PE). VTE represents the third most frequent cardiovascular disease with the annual incidence of 100-200 per 100.000 inhabitants. The consequences which may be fatal or lead to chronic disease are often preventable. The European Society of Cardiology has recently published the third release of guidelines for PE, endorsed by the European Respiratory Society. Many facts and recommendations have been retained from previous version, but very important new data and evidence have been summarized, especially on the treatment and prophylaxis of VTE with the new oral direct anticoagulants (NOACs). The principal results of phase III clinical trials with NOACs on the acute phase treatment and standard duration of anticoagulation after PE or VTE have been overviewed, as well for the extended treatment. These results strongly indicate that NOACs are non-inferior in terms of efficacy and possibly safer, particularly in terms of major bleeding, than standard treatment with heparin and vitamin K antagonists. Based on the evidence and permanently growing data, NOACs should be seriously considered as an alternative to standard tretment of VTE and used according to the recommendations published in the practical guide by the European Heart Rhythm Association.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Rijeka,
Klinički bolnički centar Rijeka
Profili:
Luka Zaputović
(autor)